Future pharmacotherapy for non-alcoholic steatohepatitis

Affiliations

Comment

Arka DE Ajay Duseja. Natl Med J India. 2021 Jul-Aug.

. 2021 Jul-Aug;34(4):225-227.

doi: 10.25259/NMJI_103_21.

¹ Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

No abstract available

Comment on

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. Newsome PN, et al. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33185364 Clinical Trial.

1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328-57
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M,. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64:73-84
1. Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019; 3:133-9
1. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015; 5:51-68
1. Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, et al. Non-alcoholic fatty liver disease-Histological scoring systems: A large cohort single-center, evaluation study. APMIS. 2017; 125:962-73